Month: December 2020
Excerpt from the Article: It goes without saying that COVID-19 has had a tremendous impact on our global society and economy. In fact, as lockdown was initiated across Europe at the start of March, we quickly saw the impact of this pandemic on clinical research activities across the various regions. Within the life sciences industry,…
Read More
Excerpt from the article: Fluvoxamine, an antidepressant used to treat obsessive-compulsive disorder, may help prevent clinical deterioration of patients with mild coronavirus disease 2019 (COVID-19), results of an early clinical trial suggest. The double-blind, placebo-controlled, randomized study, published in JAMA, included 152 outpatients with COVID-19 in the St. Louis area between April 10 and August…
Read More
Excerpt from the Press Release: TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX: PRN) (“Profound” or the “Company”) announced today that Sonalleve® has received U.S. Food and Drug Administration (“FDA”) approval under a Humanitarian Device Exemption (“HDE”) for the treatment of osteoid osteoma. Osteoid osteoma is a non-cancerous bone tumor that…
Read More
Excerpt from the Press Release: Celltrion Group has completed enrolment of 327 patients with mild-to-moderate SARS-CoV-2 infection symptoms to evaluate anti-Covid-19 monoclonal antibody treatment candidate CT-P59 in the global Phase II clinical trial. Celltrion Group has completed enrolment of 327 patients with mild-to-moderate SARS-CoV-2 infection symptoms to evaluate anti-Covid-19 monoclonal antibody treatment candidate CT-P59 in…
Read More- « Previous
- 1
- 2
- 3
- 4